HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Kezar Life Sciences (NASDAQ:KZR) and maintained a $20 price target.
October 12, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kezar Life Sciences' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $20.
The reiteration of a 'Buy' rating and a maintained price target of $20 by HC Wainwright & Co. indicates a positive outlook for Kezar Life Sciences. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100